Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multinationals Score Three Out Four New China Priority Reviews

Executive Summary

Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.

You may also be interested in...



China JV Exit To Give Takeda More Focus, Cash

Takeda is selling its majority share in China biopharma joint venture Techpool to focus on its key growth areas in this market and raise cash ahead of the Shire acquisition, in a move that will also boost its former partner’s presence in manufacturing and critical care.

Can Takeda Help Deliver Shire's China Rare Disease Dream?

Coming out of the local integration with Baxter's spin-off Baxalta in China, Shire may have to face more uncertainties in the country despite erstwhile acquirer Takeda having a much larger presence there, while competition is also brewing for the merged company from rare disease heavyweights such as Roche and Biogen.

Winter Olympics Test China's 'Zero COVID' Limits, Treatment Constraints

Amid China’s increasingly inward-looking and dual circulation economic policies, the Beijing Winter Olympics provide rare insight into policymakers’ handling of a global event.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel